Holen Sie sich die Stockscreener-App
21.00
10.92%
2.085
Handel nachbörslich:
20.99
-0.01
-0.05%
Schlusskurs vom Vortag:
$18.91
Offen:
$18.91
24-Stunden-Volumen:
5.56M
Relative Volume:
8.62
Marktkapitalisierung:
$1.27B
Einnahmen:
$688.00K
Nettoeinkommen (Verlust:
$-170.19M
KGV:
-7.0946
EPS:
-2.96
Netto-Cashflow:
$-154.68M
1W Leistung:
+30.96%
1M Leistung:
+34.06%
6M Leistung:
+61.14%
1J Leistung:
-31.57%
1-Tages-Spanne:
$18.71
$21.61
1-Wochen-Bereich:
$16.04
$21.61
52-Wochen-Spanne:
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie SYRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
21.00 | 1.14B | 688.00K | -170.19M | -154.68M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-26 | Eingeleitet | Deutsche Bank | Buy |
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Spyre Therapeutics rises after $275 mln equity raise - TradingView
Spyre Therapeutics IncExpects $486.2 million in cash and equivalents as of Sept 30, 2025SEC filing - MarketScreener
Will Spyre Therapeutics Inc. stock recover faster than peersWall Street Watch & Safe Swing Trade Setups - newser.com
Spyre Therapeutics Prices $275 Million Share Offering - MarketScreener
Spyre Therapeutics (NASDAQ:SYRE) Rating Increased to Hold at Wall Street Zen - Defense World
Will Spyre Therapeutics Inc. stock deliver strong dividend growth2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
SYRE Stock Offering Priced Below Recent Closing - GuruFocus
Spyre Therapeutics prices public offering at $18.50 per share - Investing.com
Spyre Therapeutics announces pricing of $275 million public offering of common stock - MarketScreener
$275M Offering — Spyre Therapeutics Prices 14.86M Shares for IBD Biotech - Stock Titan
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock - GlobeNewswire Inc.
Spyre Therapeutics Launches Public Offering - MarketScreener
Spyre Therapeutics announces public offering of common stock and pre-funded warrants - MSN
Spyre Therapeutics announces common stock offering, no amount given - TipRanks
Spyre Therapeutics falls after stock offering launch - TradingView
Spyre Therapeutics announces common stock offering - Investing.com India
Spyre Therapeutics Announces Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Spyre Therapeutics to Offer Common Stock & Pre-Funded Warrants; 30-Day Underwriter Option - Stock Titan
Using Python tools to backtest Spyre Therapeutics Inc. strategiesJuly 2025 Trade Ideas & Real-Time Market Sentiment Alerts - newser.com
Will Spyre Therapeutics Inc. stock pay special dividendsNew Guidance & Accurate Buy Signal Notifications - newser.com
Can Spyre Therapeutics Inc. stock sustain free cash flow growth2025 Major Catalysts & Entry Point Confirmation Signals - newser.com
Why Spyre Therapeutics Inc. stock is a value investor pickQuarterly Trade Review & High Win Rate Trade Tips - newser.com
What sentiment indicators say about Spyre Therapeutics Inc. stockJuly 2025 Momentum & Short-Term Swing Trade Alerts - newser.com
Best data tools to analyze Spyre Therapeutics Inc. stockMarket Growth Report & Stepwise Entry/Exit Trade Alerts - newser.com
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5%Here's Why - MarketBeat
Analyzing Spyre Therapeutics Inc. with risk reward ratio charts2025 Trading Recap & Stock Portfolio Risk Control - newser.com
How to integrate Spyre Therapeutics Inc. into portfolio analysis toolsJuly 2025 Institutional & Accurate Technical Buy Alerts - newser.com
Is Spyre Therapeutics Inc. a candidate for recovery playWeekly Trend Summary & Community Trade Idea Sharing Platform - newser.com
Custom strategy builders for tracking Spyre Therapeutics Inc.July 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Spyre Therapeutics' (SYRE) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Shares Up 8.9%What's Next? - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Published on: 2025-10-06 01:19:10 - newser.com
Spyre Therapeutics (SYRE) Highlights Progress at European Gastro - GuruFocus
Spyre Therapeutics Presents Promising Phase 1 Data for SPY002 at UEGW Congress - Quiver Quantitative
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 - The Manila Times
6-Month Data: Spyre's SPY002 Shows Q3M Dosing Potential; Preclinical Combos Superior - Stock Titan
Spyre Therapeutics Inc. stock volume spike explainedWeekly Investment Summary & Real-Time Market Sentiment Reports - newser.com
Tools to monitor Spyre Therapeutics Inc. recovery probability2025 Stock Rankings & Smart Money Movement Tracker - newser.com
Spyre Therapeutics Inc. stock daily chart insightsEarnings Performance Report & Safe Capital Growth Trade Ideas - newser.com
Is Spyre Therapeutics Inc. (3920) stock inflation resilientMarket Risk Analysis & AI Driven Price Predictions - newser.com
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
42,500 Stock Options — Spyre Therapeutics Grants Options at $16.46 to Three Non‑Executive Employees - Stock Titan
What Fibonacci levels say about Spyre Therapeutics Inc. reboundJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
What candlestick patterns are forming on Spyre Therapeutics Inc.Trend Reversal & Weekly High Conviction Ideas - newser.com
Why millennials buy Spyre Therapeutics Inc. (3920) stockTrade Risk Report & Smart Swing Trading Techniques - newser.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $54.29 Average PT from Brokerages - Defense World
What analysts say about Spyre Therapeutics Inc 3920 stockStock Watchlist Updates & Low Risk Capital Growth - earlytimes.in
What technical charts say about Spyre Therapeutics Inc. stockJuly 2025 Snapshot & Daily Profit Focused Screening - newser.com
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):